0VRQ Stock Overview
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
CRISPR Therapeutics AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$53.59 |
52 Week High | US$91.00 |
52 Week Low | US$37.58 |
Beta | 1.74 |
1 Month Change | -24.27% |
3 Month Change | -12.72% |
1 Year Change | 8.95% |
3 Year Change | -59.71% |
5 Year Change | n/a |
Change since IPO | 35.84% |
Recent News & Updates
Recent updates
Shareholder Returns
0VRQ | GB Biotechs | GB Market | |
---|---|---|---|
7D | -2.3% | -0.4% | 2.2% |
1Y | 9.0% | -29.1% | 0.9% |
Return vs Industry: 0VRQ exceeded the UK Biotechs industry which returned -29.1% over the past year.
Return vs Market: 0VRQ exceeded the UK Market which returned 0.9% over the past year.
Price Volatility
0VRQ volatility | |
---|---|
0VRQ Average Weekly Movement | 7.8% |
Biotechs Industry Average Movement | 6.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0VRQ's share price has been volatile over the past 3 months.
Volatility Over Time: 0VRQ's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 407 | Sam Kulkarni | www.crisprtx.com |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.
CRISPR Therapeutics AG Fundamentals Summary
0VRQ fundamental statistics | |
---|---|
Market cap | US$4.56b |
Earnings (TTM) | -US$153.61m |
Revenue (TTM) | US$371.21m |
12.3x
P/S Ratio-29.7x
P/E RatioIs 0VRQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0VRQ income statement (TTM) | |
---|---|
Revenue | US$371.21m |
Cost of Revenue | US$517.58m |
Gross Profit | -US$146.38m |
Other Expenses | US$7.23m |
Earnings | -US$153.61m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.81 |
Gross Margin | -39.43% |
Net Profit Margin | -41.38% |
Debt/Equity Ratio | 0% |
How did 0VRQ perform over the long term?
See historical performance and comparison